Newsroom | 5138 results

MALVERN, Pa.--(BUSINESS WIRE)--LifeScan (the "Company"), a world leader in blood glucose monitoring, today announced the appointment of Jonathan Salkin as Chief Executive Officer, effective immediately. Salkin will succeed Michael Hooks and James Rushing who have been serving as Co-Interim CEOs since January 2026. Hooks will continue to serve as Chairman of the Board and Rushing will continue in his roles as Executive Vice President and Chief Financial Officer. Salkin joins LifeScan with more t...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and exceeded the high end of the Company’s guidance range of 25% - 27% at constant currency rates Total Omnipod revenue of $758.4...

BERLIN & SAN FRANCISCO--(BUSINESS WIRE)--Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic R...

BREMA, Germania--(BUSINESS WIRE)--Kerecis, l'azienda pioniera nell'utilizzo della pelle di pesce intatta ottenuta in modo sostenibile nella terapia cellulare e nella rigenerazione dei tessuti, avrà un importante ruolo scientifico e pedagogico alla EWMA‑DEWU 2026 Conference, che si svolgerà il 6-8 maggio al Messe & Congress Centrum Bremen a Brema, Germania. Quest'anno, l'incontro della European Wound Management Association (EWMA) si terrà insieme al Deutscher Wundkongress (DEWU), unendo due...

BREMEN, Duitsland--(BUSINESS WIRE)--Kerecis, het bedrijf dat baanbrekend werk verricht op het gebied van het gebruik van duurzaam gewonnen intacte vissenhuid in celtherapie en weefselregeneratie, zal een prominente rol spelen op wetenschappelijk en educatief vlak tijdens de EWMA-DEWU 2026-conferentie, die van 6 tot en met 8 mei plaatsvindt in het Messe & Congress Centrum Bremen in Bremen, Duitsland Dit jaar wordt de bijeenkomst van de European Wound Management Association (EWMA) gezamenlijk...

BRÊME, Allemagne--(BUSINESS WIRE)--Kerecis, société pionnière dans l’utilisation de peau de poisson intacte issue de sources durables pour la thérapie cellulaire et la régénération tissulaire, jouera un rôle scientifique et éducatif de premier plan lors de la conférence EWMA-DEWU 2026, qui se tiendra du 6 au 8 mai au Messe & Congress Centrum Bremen à Brême, en Allemagne. Cette année, la réunion de l’Association européenne pour la gestion des plaies (EWMA) se tient conjointement avec le Deut...

BREMEN, Alemania--(BUSINESS WIRE)--Kerecis, la empresa pionera en la aplicación de piel de pescado intacta de origen sostenible a la terapia celular y regeneración de tejidos, desempeñará un papel científico y educativo destacado en el Congreso EWMA-DEWU 2026, que se realizará del 6 al 8 de mayo en el Messe & Congress Centrum Bremen, en Bremen, Alemania. Este año, la reunión de la Asociación Europea para el Manejo de las Heridas (European Wound Management Association, EWMA) se celebra conju...

BREMEN, Deutschland--(BUSINESS WIRE)--Kerecis, das Unternehmen, das Pionierarbeit bei der Verwendung von intakter Fischhaut aus nachhaltiger Herkunft in der Zelltherapie und Geweberegeneration leistet, wird auf der EWMA-DEWU-Konferenz 2026, die vom 6. bis 8. Mai im Messe- und Kongresszentrum Bremen in Bremen stattfindet, eine herausragende Rolle in den Bereichen Wissenschaft und Bildung spielen. In diesem Jahr findet die Tagung der European Wound Management Association (EWMA) gemeinsam mit dem...

FONTANA, Wis. & MIAMI--(BUSINESS WIRE)--The Global Initiative for Asthma (GINA) collaborates with OpenEvidence to make GINA’s evidence-based asthma strategy reports, clinical recommendations, and educational resources available directly through OpenEvidence. Under the agreement, OpenEvidence becomes a key content partner for GINA, driving the digital dissemination of asthma standards to clinicians across OpenEvidence’s rapidly expanding international footprint. Asthma affects more than 300 mill...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowhead’s clinical stage RNA interference (RNAi) therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH). “The early clinical data for ARO-PNPLA3 h...